FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200278360> ?p ?o ?g. }

• W4200278360 abstract "Abstract Aims MitraClip treatment has been recently proposed as a ‘bridge strategy’ solution for advanced heart failure (HF) patients with significant functional mitral regurgitation (MR), who are potential candidates or are waiting for cardiac replacement therapy (LVAD or heart transplantation, HTx). In this clinical scenario, left-ventricular-related right ventricular dysfunction (RVD) represents an important prognostic factor. Our study aimed to investigate the possible prognostic implication of RVD in advanced HF patients treated with MitraClip as a bridge to HTx strategy. Methods and results RVD was assessed using the relationship between tricuspid annular peak systolic excursion (TAPSE) and pulmonary artery systolic pressure (PASP). All patients from the MitraBridge registry for whom these two echocardiographic parameters were available, were included in the study. A cut-off value of TAPSE/PASP ratio &lt; 0.36 was used to defined RVD, as previously reported. The primary outcome was a composite Endpoint of all-cause death or rehospitalization for HF at 2-year. For patients who underwent LVAD implantation or HTx, follow-up data were censored at the time of those events. A total of 80 patients were included in the study. The median TAPSE/PASP ratio was 0.35 (25th–75th: 0.27–0.46), with 43 (54%) patients having a TAPSE/PASP ratio &lt; 0.36 (RVD group). The latter had a prevalent MR ischaemic etiology (49% vs. 38%), with a more frequent history of percutaneous coronary intervention (46.5% vs. 22%, P = 0.02). Except for TAPSE (15.7 ± 3.6 mm vs. 19.2 ± 3.7 mm, P = 0.001) and PASP (61 ± 14 mmHg vs. 39.5 ± 9.5 mmHg, P &lt; 0.001), the other echocardiographic characteristics were similar between the two study groups (overall mean left ventricular ejection fraction 26.9 ± 8%, median left ventricular end-diastolic volume index 120.7, 25th–75th: 102.2–146.5 ml/m2). After a median follow-up time of 508 (25th–75th: 160–899) days, elective HTx occurred in 12 patients (7 from the RVD group), while LVAD implantation was performed in 13 patients (7 from the RVD group). The primary outcome occurred in 30 patients (38%) with a 2-year Kaplan–Meier estimate of freedom from the composite endpoint of 41%. At univariate (HR: 1.3; 95% CI: 0.6–2.8, P = 0.451) and multivariate (HR: 1.6; CI: 0.7–3.8, P = 0.249) Cox-regression analysis, TAPSE/PASP ratio &lt; 0.36 was not identified as an independent predictor of primary outcome. Indeed, at follow-up echocardiographic control (median time 252, 25th–75th: 122–365 days), a significant improvement in TAPSE/PASP ratio was observed in the RVD group (baseline median TAPSE/PASP ratio 0.27, 25th–75th: 0.22–0.32 vs. follow-up median TAPSE/PASP ratio 0.37, 25th–75th: 0.28–0.47, P &lt; 0.001). Conclusions In advanced HF patients with functional MR, MitraClip treatment could prevent or ameliorate left-ventricular-related RVD, allowing safe access to HTx or LVAD." @default.
• W4200278360 created "2021-12-31" @default.
• W4200278360 creator A5002130530 @default.
• W4200278360 creator A5016167046 @default.
• W4200278360 creator A5026057493 @default.
• W4200278360 creator A5027648695 @default.
• W4200278360 creator A5030482424 @default.
• W4200278360 creator A5036972757 @default.
• W4200278360 creator A5051104101 @default.
• W4200278360 creator A5051869176 @default.
• W4200278360 creator A5061633277 @default.
• W4200278360 creator A5067452636 @default.
• W4200278360 creator A5067607910 @default.
• W4200278360 creator A5068927524 @default.
• W4200278360 creator A5072957878 @default.
• W4200278360 creator A5078420550 @default.
• W4200278360 creator A5079119550 @default.
• W4200278360 creator A5081019858 @default.
• W4200278360 date "2021-12-01" @default.
• W4200278360 modified "2023-09-25" @default.
• W4200278360 title "630 Impact of right ventricular dysfunction after mitraclip treatment as a bridge to heart transplantation: insight from the mitrabridge strategy" @default.
• W4200278360 doi "https://doi.org/10.1093/eurheartj/suab139.033" @default.
• W4200278360 hasPublicationYear "2021" @default.
• W4200278360 type Work @default.
• W4200278360 citedByCount "0" @default.
• W4200278360 crossrefType "journal-article" @default.
• W4200278360 hasAuthorship W4200278360A5002130530 @default.
• W4200278360 hasAuthorship W4200278360A5016167046 @default.
• W4200278360 hasAuthorship W4200278360A5026057493 @default.
• W4200278360 hasAuthorship W4200278360A5027648695 @default.
• W4200278360 hasAuthorship W4200278360A5030482424 @default.
• W4200278360 hasAuthorship W4200278360A5036972757 @default.
• W4200278360 hasAuthorship W4200278360A5051104101 @default.
• W4200278360 hasAuthorship W4200278360A5051869176 @default.
• W4200278360 hasAuthorship W4200278360A5061633277 @default.
• W4200278360 hasAuthorship W4200278360A5067452636 @default.
• W4200278360 hasAuthorship W4200278360A5067607910 @default.
• W4200278360 hasAuthorship W4200278360A5068927524 @default.
• W4200278360 hasAuthorship W4200278360A5072957878 @default.
• W4200278360 hasAuthorship W4200278360A5078420550 @default.
• W4200278360 hasAuthorship W4200278360A5079119550 @default.
• W4200278360 hasAuthorship W4200278360A5081019858 @default.
• W4200278360 hasBestOaLocation W42002783601 @default.
• W4200278360 hasConcept C126322002 @default.
• W4200278360 hasConcept C141071460 @default.
• W4200278360 hasConcept C164705383 @default.
• W4200278360 hasConcept C2778198053 @default.
• W4200278360 hasConcept C2778774980 @default.
• W4200278360 hasConcept C2778849806 @default.
• W4200278360 hasConcept C2779326848 @default.
• W4200278360 hasConcept C2780400711 @default.
• W4200278360 hasConcept C2780793704 @default.
• W4200278360 hasConcept C2780940725 @default.
• W4200278360 hasConcept C2911091166 @default.
• W4200278360 hasConcept C2993373945 @default.
• W4200278360 hasConcept C500558357 @default.
• W4200278360 hasConcept C71924100 @default.
• W4200278360 hasConceptScore W4200278360C126322002 @default.
• W4200278360 hasConceptScore W4200278360C141071460 @default.
• W4200278360 hasConceptScore W4200278360C164705383 @default.
• W4200278360 hasConceptScore W4200278360C2778198053 @default.
• W4200278360 hasConceptScore W4200278360C2778774980 @default.
• W4200278360 hasConceptScore W4200278360C2778849806 @default.
• W4200278360 hasConceptScore W4200278360C2779326848 @default.
• W4200278360 hasConceptScore W4200278360C2780400711 @default.
• W4200278360 hasConceptScore W4200278360C2780793704 @default.
• W4200278360 hasConceptScore W4200278360C2780940725 @default.
• W4200278360 hasConceptScore W4200278360C2911091166 @default.
• W4200278360 hasConceptScore W4200278360C2993373945 @default.
• W4200278360 hasConceptScore W4200278360C500558357 @default.
• W4200278360 hasConceptScore W4200278360C71924100 @default.
• W4200278360 hasIssue "Supplement_G" @default.
• W4200278360 hasLocation W42002783601 @default.
• W4200278360 hasOpenAccess W4200278360 @default.
• W4200278360 hasPrimaryLocation W42002783601 @default.
• W4200278360 hasRelatedWork W1520723865 @default.
• W4200278360 hasRelatedWork W1991639333 @default.
• W4200278360 hasRelatedWork W2143015101 @default.
• W4200278360 hasRelatedWork W2203560198 @default.
• W4200278360 hasRelatedWork W2394921944 @default.
• W4200278360 hasRelatedWork W2407717929 @default.
• W4200278360 hasRelatedWork W2774859156 @default.
• W4200278360 hasRelatedWork W2920043851 @default.
• W4200278360 hasRelatedWork W3099497794 @default.
• W4200278360 hasRelatedWork W4200278360 @default.
• W4200278360 hasVolume "23" @default.
• W4200278360 isParatext "false" @default.
• W4200278360 isRetracted "false" @default.
• W4200278360 workType "article" @default.